Smartlab Europe

News

Australia Injects $5.5 M To Heal Low Survival Breast Cancers

In a development that gives a big sigh of relief to the breast cancer fraternity, funding of a couple of clinical trials which could save lives with the help of new therapies, has been done, all thanks to Australia’s...

ICRA Sees Growth In Indian Pharma Industry By 9-11% In FY22

Driven by the push from emerging as well as domestic markets in the upcoming quarters, the Indian Pharma industry in the Financial Year-22 is expected to be pegged at 9-11 percent, says credit rating agency, ICRA. ICRA’s sample of...

Ashfield Engage, Alliance Medical and NHS partner to identify early-stage lung cancer

Ashfield Engage, part of UDG Healthcare, has partnered with Alliance Medical to forge a new collaboration delivering the Targeted Lung Health Check (TLHC) programme on behalf of Doncaster and Bassetlaw CCG. The programme is running across 12 pilot sites...

FDA Nod Given To Wuxi STA Shanghai Facility After Inspection

WuXi AppTec’s WuXi STA has said that its facility at Waigaoqiao near Shanghai has cleared its first FDA drug product pre-approval inspection. Notably, the U.S. regulator had finished off the inspection in five days last year October. The review...

ChargePoint Technology Acquires Terracon Corporation

ChargePoint Technology, the powder transfer specialist, has today announced the acquisition of Terracon Corporation a leader in the design, development, and manufacture of single-use products and accessories for mixing, transferring, and storing liquids and fluids in the biopharma and...

In-Vitro Biology Capabilities Expanded By Piramal Pharma

Piramal Pharma Solutions has confirmed that it has put in a multi-million dollar investment to create a top-notch screening facility that will elevate the in-vitro biology capabilities of its drug discovery service site at Ahmedabad in India. The new expansion...

Ascletis expands production of ritonavir oral tablets & oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 infection

Ascletis Pharma Inc. announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The company’s Covid-19 pipeline currently includes (i) ritonavir oral tablet (100 mg), an authorized...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »